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Promoter hypermethylation of CpG islands in tumour suppressor genes can lead to transcriptional inactivation. To investigate
the association between methylation and expression at O
6-methylguanine-DNA methyltransferase, we performed methylation-
speciﬁc PCR and immunohistochemistry in 149 gastric carcinomas. Promoter methylation was found in 14.1% of tumours and
loss of expression was detected in 11.4% of tumours. To examine correlation between the O
6-methylguanine-DNA
methyltransferase expression and the clinical data, we investigated O
6-methylguanine-DNA methyltransferase expression in 315
consecutive gastric carcinomas. A similar frequency of loss of O
6-methylguanine-DNA methyltransferase expression was
conﬁrmed in these cases. The loss of O
6-methylguanine-DNA methyltransferase expression was signiﬁcantly associated with
pTNM stage (P=0.037), tumour invasion (P=0.02), microsatellite instability (P=0.041) and overall survival (P=0.01). Among 11
gastric cancer cell lines, SNU-620 showed the loss of O
6-methylguanine-DNA methyltransferase expression as well as promoter
methylation. After treatment with 5-aza-2-deoxycytidine, a demethylating agent, SNU-620 re-expressed O
6-methylguanine-DNA
methyltransferase mRNA. In summary, we suggest that during gastric carcinogenesis, the loss of O
6-methylguanine-DNA
methyltransferase expression frequently occurs via the hypermethylation of the CpG islands of the promoter region, and that
this is signiﬁcantly associated with the clinicopathological characteristics.
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Epigenetics is deﬁned as an inheritable effect that inﬂuences gene
activity but does not involved a change in the DNA sequence.
DNA methylation is one of these epigenetic changes in human
cancer and is involved in gene silencing. About 60% of human
genes have CpG islands at the 5' region of their DNA sequence.
This region contains the promoter and the exons and is normally
unmethylated (Toyota et al, 2000). Aberrant methylation of CpG
islands in tumour suppressor genes can lead to transcriptional
inactivation. Promoter hypermethylation of CpG islands of tumour
suppressor genes (p16, p14, and APC), DNA repair genes (hMLH1
and MGMT) and genes related to metastasis and invasion (E-
cadherin, TIMP-3, and DAPK) has been shown in various cancers
and is associated with the loss of expression (Yoshiura et al,
1995; Herfarth et al, 1999; Eads et al, 2001; Esteller et al, 2001a;
Rosas et al, 2001 Zo ¨chbauer-Mu ¨ller et al, 2001).
O
6-methylguanine-DNA methyltransferase (MGMT) is a DNA
repair gene, which removes methyl groups as well as larger adducts
at O
6 position of guanine. MGMT transfers the alkyl group from
O
6-guanine in DNA to an active cysteine within its own sequence
in a reaction that inactivates one MGMT molecule for each lesion
repaired (Pegg, 1990; Esteller et al, 1999). Methylating agents such
as N-methyl-N-nitrosourea (MNU) and N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG) react with guanine in DNA to form
O
6-methylaguanine. The alkylation of DNA at the O
6 position of
guanine is associated with formation of DNA mutation in cancers,
such as the transition of guanine-cytosine to adenine-thymine pairs
in the K-ras mutation or in p53, which occurs because alkylated
guanine is recognised as adenine during DNA replication (Esteller
et al, 2000a, 2001b; Whitehall et al, 2001).
Methylation of the MGMT gene has been reported in various
carcinomas. In gliomas and colorectal cancers, methylation was
shown in 38% of the tumour, whereas in non-small cell lung carci-
nomas, lymphomas, and head and neck carcinomas, methylation
was demonstrated in 23–28% of tumours (Esteller et al, 1999;
Rosas et al, 2001). Promoter hypermethylation of MGMT in
colorectal carcinomas results in transcriptional inactivation of
MGMT gene (Esteller et al, 2000a).
We examined the loss of expression and the promoter methylation
of MGMT in 149 gastric carcinomas and 11 gastric cancer cell lines
and investigated an association with loss of expression and clinico-
pathological characteristics in consecutive gastric carcinomas.
MATERIALS AND METHODS
Primary gastric cancer tissue samples
Initially, 149 stomach carcinomas and matched normal tissues
were obtained from surgical resection specimens at Seoul
National University Hospital from 1998 to 1999. All samples
were ﬁxed using absolute methanol, processed in chloroform
and DNA was extracted by the phenol-chloroform methods.
Formalin-ﬁxed, parafﬁn embedded samples were arranged into
three tissue array blocks. In addition to the 149 stomach carci-
noma specimens, 315 consecutive cases of formalin-ﬁxed,
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www.bjcancer.comparafﬁn embedded stomach specimens were arranged into six
tissue array blocks (Lee et al, 2001). None of the patients
received preoperative chemo- or radiotherapy. These array blocks
were cut into 4 um sections, and deparafﬁnized and dehydrated.
Immunohistochemistry was carried out using a Vector ABC kit
(Vector Laboratories, Inc., Burlingame, CA, USA) and mouse
anti-MGMT monoclonal antibody (Chemicon, Temecula, CA,
USA) at a dilution of 1:50.
Gastric cancer cell lines
Eleven gastric cancer cell lines, SNU-1, -5, -16, -216, -484, -520,
-601, -620, -638, -668, and -719, were obtained from the Korean
Cell Line Bank (Seoul, Korea). They were cultured in RPMI-1640
(Life Technologies, Rockville, MD, USA) supplemented with 10%
heat-inactivated FBS (Hyclone, Logan, UT, USA).
For Western blot analysis, cell lines were harvested with PBSTDS
containing 1% Trition X-100, 0.5% sodium deoxycholate,
and 0.1% SDS. Equal amounts of protein, as determined by a
bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA), were
dissolved in sample buffer, separated by electrophoresis on 12%
SDS-polyacrylamide gel and transferred to a polyvinylidene diﬂuor-
ide membrane (Millipore Corp., Bedford, MA, USA). The
membrane was blocked with 3% non-fat dry milk in tris buffer-
saline with 0.1% Tween 20 for 1 h at room temperature and incu-
bated with the mouse anti-MGMT monoclonal antibody (1:500,
Chemicon) at 48C overnight. The membrane was then washed in
the same buffer, incubated in horseradish peroxidase conjugated
anti-mouse antibody (Amersham Pharmacia, Buckinghamshire,
UK) for 30 min at room temperature, and then immersed in an
enhanced chemiluminescence (ECL) Western blotting detection
system (Amersham Pharmacia).
For reverse transription-PCR, total RNA of the gastric cancer
cell lines was extracted using Trizol (LifeTechnologies) and 0.5
ug of the total RNA was used to generate cDNA. This cDNA
was ampliﬁed with primers, 5'-GTG GGA GGA GCA ATG AGA
GG-3' and 5'-TCC CGC TCC CTT GAG CCA GG-3' (Watts et
al, 1997). The primers for b-actin, the positive control, were 5'-
ACA CTG TGC CCA TCT ACG AGG-3' and 5'-AGG GGC CGG
ACT CGT CAT ACT-3'. The PCR products obtained were analysed
by 1.5% agarose gel electrophoresis with ethidium bromide and
examined under UV light.
In order to demethylate the methyl-CpG sites of DNA, cell lines
were cultured in a 100 mm culture dish (Nunc, Roskilde,
Denmark) and were treated with 10 uM of 5-aza-2'-deoxycytidine
(Sigma, St. Louis, MO, USA) for 10 days.
Methylation-speciﬁc PCR
DNA modiﬁcation was carried out according to the procedure
described by Frommer et al (1992). One ug of DNA was denatured
for 5 min at 948C, 10 ul of 1 N HCl was then added, and the
mixture was incubated for 10 min at 378C. The denatured DNA
obtained was modiﬁed using 3.5 M sodium bisulphite per 1 mM
hydroquinone (pH 5.0) for 16 h at 508C, and the modiﬁed DNA
were then puriﬁed using a Wizard DNA clean-up system (Promega,
Madison, WI, USA). Fifteen ul of 1 N HCl was added to the puri-
ﬁed DNA, which was then precipitated with ethanol, and
resuspended in 20 ul of water.
After the sodium bisulphite modiﬁcation, the DNA was ampli-
ﬁed in a volume of 10 ul with methylation speciﬁc primers
(Esteller et al, 1999). The primers for methylated DNA were sense
5'- TTT CGA CGT TCG TAG GTT TTC GC-3' and antisense 5'-
GCA CTC TTC CGA AAA CGA AAC G-3'. The primers for
unmethylated DNA were sense 5'-TTT GTG TTT TGA TGT
TTG TAG GTT TTT GT-3' and antisense 5'-AAC TCC ACA
CTC TTC CAA AAA CAA AAC A-3'. The ampliﬁcation conditions
were as followed: 958C for 5 min; followed by 33 cycles of 948C for
30 s, 598C for 30 s, and 728C for 40 s; followed by ﬁnal extension
of 728C for 10 min. PCR products were electrophoresed on 6%
polyacrylamide gel, stained with ethidium bromide, and visualised
under UV illumination (Herman et al, 1996).
Sodium bisulphite genomic sequencing
After the sodium bisulphite modiﬁcation, the DNA was ampliﬁed
using hemi-nested primers. The primers were sense, 5'-TTA AGG
TAT AGA GTT TTA GGC GGA AGT TGG-3', nested sense, 5'-
TTT AGC GAG GAT GTG TAG ATT GTT TTA GGT-3', and anti-
sense, 5'-AAA ACG AAA CGA CCC AAA CAC TCA CCA AAT-3'
(Qian and Brent, 1997). The ampliﬁcation conditions were as
followed: 958C for 5 min; followed by 33 cycles of 948C for 30 s,
628C for 30 s, and 728C for 40 s; followed by ﬁnal extension of
728C for 10 min. The ﬁrst round PCR products were puriﬁed with
High Pure PCR product puriﬁcation kit (Boehringer Manheim,
Mannheim, Germany). The ﬁnal hemi-nested PCR products were
ampliﬁed at an annealing temperature of 648C. The ampliﬁed
PCR products were puriﬁed using a PCR product pre-sequencing
kit (Amersham Pharmacia) and sequencing was carried out with
a BigDye Terminator Cycle Sequencing Ready Reaction kit (Perkin
Elmer, Foster City, CA, USA) using an ABI Prism 377 DNA
sequencer (Perkin Elmer).
Statistics
Statistical analysis was performed using SPSS 9.0 software (SPSS,
Chicago, IL, USA). Associations between the discrete variables were
assessed using the two-sided Fisher’s exact test or Pearson’s chi
square tests. Overall survival was calculated by Kaplan–Meier
log-rank test. Multivariate analysis to assess the independent prog-
nostic value of MGMT staining was performed by Cox regression.
P value less than 0.05 was regarded as statistically signiﬁcant.
RESULTS
Promoter methylation and loss of MGMT expression in 149
gastric carcinomas
To examine promoter methylation, we carried out methylation-
speciﬁc PCR in the 149 methanol-ﬁxed gastric carcinomas. Methy-
lation was detected in 14.1% (21/149) of tumours. None of the
matched normal tissues showed methylated bands (Figure 1A).
To investigate expression, we applied tissue array method and
carried out immunohistochemistry in formalin-ﬁxed gastric carci-
nomas. MGMT protein was normally expressed in the nucleus of
most parenchymal and stromal cells (Figure 2A). Seventeen cases
(17/149, 11.4%) of tumours showed complete loss of MGMT
expression (Figure 2B) and 13 cases of these (76.5%) were methy-
lated in promoter region. Out of the 132 tumours with MGMT
expression, eight tumours (6.1%) showed methylation, and among
these eight cases, three showed loss of MGMT expression in the
focal area of the tumour (Figure 2C). In chi square test, promoter
hypermethylation of MGMT was signiﬁcantly associated with a loss
of expression in gastric carcinomas (Table 1, P50.001).
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 1 Promoter methylation and protein expression of MGMT in 149
gastric carcinomas
Methylation-speciﬁc PCR
Immunohistochemistry Unmethylation Methylation Total
+ 124 8 132
7 41 3 1 7
Total 128 21 149
P50.001.
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consecutive gastric carcinomas
To investigate the association between the loss of MGMT expres-
sion and the clinicopathologic characteristics, we carried out
immunohistochemistry using six tissue array blocks containing
315 consecutive gastric carcinomas with the follow-up data. Loss
of MGMT expression was found in 13.3% of tumours and was
signiﬁcantly associated with pTNM stage (P=0.037), and tumour
invasion (P=0.02). We previously investigated microsatellite status
using BAT-25 and BAT-26 markers in 315 gastric cancers (accepted
in Modern Pathol). Loss of MGMT expression was signiﬁcantly
associated with microsatellite instability (P=0.041) (Table 2).
Furthermore, patients with the loss of MGMT expression had a
poorer prognosis than those with a normal expression pattern
(P=0.01) (Figure 3). In the multivariate analysis, MGMT did not
demonstrate a correlation with survival, when simultaneously
assessed with age, stage, histology, and lymph node metastasis
(P=0.16).
Promoter methylation and loss of expression in gastric
cancer cell lines
Promoter methylation was detected in the SNU-620 and SNU-719
cell lines. The SNU-620 cell line contained only methylated allele
but SNU-719 contained both unmethylated and methylated alleles
(Figure 1B). To compare MGMT expression vs methylation,
Western blot analysis and RT–PCR were performed. The protein
and the mRNA of MGMT were absent in the SNU-620 cell line
(Figure 4A,B). To conﬁrm the methylation status of the CpG site,
we performed bisulphite genomic sequencing of the nt 7128 to
744 promoter region. In the SNU-620 cell line, which contained
only the methylated allele, 9 of 14 CpG sites (7125, 7122,
7106, 790, 774, 770, 763, 752, and 746) were found to
be completely methylated (data not shown). The signiﬁcance of
the methylation status upon MGMT expression in vitro was
conﬁrmed by adding a demethylating agent to SNU-620, which
does not express MGMT mRNA. After 10 days of treatment with
10 uM 5-aza-2'-deoxycytidine, MGMT mRNA was detected by
RT–PCR (Figure 3C).
DISCUSSION
Normal tissues exhibit methylation in CpG sites in exons randomly
and global hypomethylation occurs in these methylated CpG sites
during carcinogenesis (Toyota et al, 2000). In contrast, CpG sites
in the promoter regions of many tumour suppressor genes are
normally unmethylated but are heavily methylated in cancer tissue
(Esteller, 2000b). In the present study, promoter methylation was
detected in 14.1% of gastric carcinomas and a loss of MGMT
expression was found in 11.4–13.3% of tumours. Our result is
lower than those of Oue et al (2001) or Park et al (2001) but is
similar to those of Esteller et al (2001a). The study by Park et al
(2001) showed that there was no signiﬁcant difference in the
protein expression between cases with MGMT methylated and
unmethylated tumours. But in our results, as well as the study
by Oue et al (2001), there were signiﬁcant differences associated
between the loss of MGMT protein expression and promoter
methylation (P50.001).
Among the cases with a loss of MGMT expression, 76.5% were
methylated while 6.1% of tumours were methylated in cases show-
ing MGMT expression. Furthermore in tumours showing both
MGMT expression and promoter methylation, three cases showed
loss of expression in the focal area of the tumour, i.e., 1 or 2 glands
in intestinal type or a small area in diffuse type (Figure 2C).
Because MGMT protein was expressed in more than 10% of the
above cases, they were regarded positive. Due to high sensitivity
of methylation-speciﬁc PCR, the methylated band may be observed
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Figure 1 Methylation-speciﬁc PCR result of MGMT in primary gastric carcinomas and the gastric cancer cell lines. (A) In gastric carcinomas, matched
normal tissues (N) showed only unmethylated bands but tumours (T) showed both unmethylated and methylated bands. (B) The SNU-620 cell line showed
only the methylated allele but the SNU-719 cell line showed both methylated and unmethylated alleles. Methylated product was not detected in other cell
lines. U, unmethylated allele; M, methylated allele.
Table 2 Association between loss of MGMT expression and clinico-
pathologic characteristics in 315 consecutive gastric carcinomas
Immunohistochemistry
7 + Total P value
Tumour invasion 0.020
EGC 5 97 102
AGC 37 176 213
pTNM stage 0.037
I 9 132 141
II 12 49 61
III 11 57 68
IV 10 35 45
Microsatellite instability status 0.041
MSS 34 244 278
MSI 8 21 29
EGC, early gastric carcinoma; AGC, advanced gastric carcinoma; MSS, microsatellite
stable; MSI, microsatellite instable.
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the 315 consecutive cases examined, 12 cases showed focal loss of
MGMT expression and eight of these cases were at stage I or II.
Therefore, it appears that during carcinogenesis, methylated cancer
cells in a small region may expand clonally, and subsequently
dominate the whole tumour tissue.
To investigate an association between MGMT expression and clin-
icopathological characteristics, we additionally investigated MGMT
expression in consecutive cases and compared the results with clin-
icopathologic data. Cases with loss of MGMT expression were
associated with advanced gastric cancer (P=0.02) and microsatellite
instability (P=0.041) and cases with MGMT expression were asso-
ciated with longer survival (P=0.01).
Recently, several studies concerning the relations between MGMT
and MSI was reported (Whitehall et al, 2001; Laiho et al, 2002) and
Yamamoto et al (2002) revealed that the sporadic
colorectal cancers with MSI-H showed frequently methylation
pattern in various genes and showed MGMT promoter methylation
in 23% of the cases. In our gastric cancer cases, the loss of MGMT
expression is signiﬁcantly associated with microsatellite instability
(P=0.041) as well as with hMLH1 expression (P=0.002, data not
shown). Our results may suggest that cancers with simultaneous
methylation of CpG islands, so-called CpC islands methylator pheno-
type or CIMP+, may demonstrate the promoter methylation of both
MGMT and hMLH1 genes. In addition, cells with loss of MGMT
expression are left unprotected from mutagens and may predispose
to additional mutations in the genes involved in the progression of
tumours which may lead to advanced stage and poor survival.
In SNU-620 cell line, which contains only methylated allele, loss
of MGMT protein and mRNA expression were reversed with treat-
ment of 5-aza-2'-deoxycytidine, a demethylating agent. It may
support that the promoter methylation of MGMT could silence
the protein expression in gastric cancer cells.
In summary, we suggest that during gastric carcinoma progres-
sion, loss of expression at the MGMT gene is frequently caused by
promoter hypermethylation of CpG islands and that this is signiﬁ-
cantly associated with tumour progression and prognosis.
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Figure 3 Overall survival of the gastric cancer patients according to
MGMT expression. Cases with loss of MGMT expression showed poor
prognosis compared to those with normal expression pattern (P=0.01).
Figure 2 Expression of MGMT in gastric carcinomas. On immunohisto-
chemistry, MGMT protein expressed in the nuclei of normal cells and can-
cer cells (A). In some cases, nuclear MGMT expression is lost completely
(B) or focally (C).
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Figure 4 Expression of MGMT in gastric cancer cell lines. (A) Protein expression by Western blot analysis. All but SNU-620 cell line express MGMT
protein. (B) mRNA expression by RT–PCR. MGMT mRNA was not detected in the SNU-620 cell line. b-actin was used as a control. (C) MGMT mRNA
expression after 5-aza-2'-deoxycytidine treatment. The SNU-620 cell line expressed mRNA after 10 uM of 5-aza-2'-deoxycytidine treatment for 10 days.
The SNU-1 was used as a positive control.
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